Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.

Journal of gastroenterology and hepatology - 1 Feb 2012

Lee Yoon-Seon, Chung Young-Hwa, Kim Jeong A, Jin Young Joo, Park Won Hyung, Kim Sung Eun, Lee Danbi, Shim Ju Hyun, Kim Kang Mo, Lim Young Suk, Lee Han Chu, Lee Yung Sang, Suh Dong Jin

Abstract excerpt

BACKGROUND AND AIM: We intended to investigate the effects of pre-existing mutations at reverse transcriptase region of hepatitis B virus (HBV) on the occurrence of virological breakthrough (VB) to adefovir dipivoxil (ADV) in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB). METHODS: Ninety-seven patients with LAM-resistant CHB were treated with ADV at a dose of 10 mg daily, and were followed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Organophosphonates

Share to Proportional Hazards Models

Share to Republic of Korea

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Source

Identifiers

PMID: 21777282
DOI: 10.1111/j.1440-1746.2011.06853.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.PMID 21777282Read ↗

Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.Semantic proximity Read ↗

Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.Semantic proximity Read ↗

YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.Semantic proximity Read ↗

Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.Semantic proximity Read ↗

Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.Semantic proximity Read ↗

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.Semantic proximity Read ↗

[Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].Semantic proximity Read ↗

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.Semantic proximity Read ↗

Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.Semantic proximity Read ↗

Clinical significance of periodic detection of hepatitis B virus YVDD mutation by ultrasensitive real-time amplification refractory mutation system quantitative PCR during lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.